Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734(TM)) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale on Day 11.
GS-US-540-5774: A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734TM) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment
- ClinicalTrials.gov Identifier: NCT04292730
- Protocol Number: 2020C000249
- Principal Investigator: Kathryn Stephenson
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required